CCHE genomics team recently published a research paper in the Cancer biomarker journal, that confirms the positive relevance /correlation between a specific gene expression in a patient’s blood and early tumor detection in AML patients
Early detection contributes to better clinical outcomes for AML patients who make up to 20%of pediatric leukemia and account for 25-35% of deaths from this type of cancer. The study has approved the miR-370 gene expression in a patient’s blood as a non-invasive biomarker used for early detection of malignancy. Detecting gene expression levels can be used for cancer diagnosis, prognosis, and treatment prediction in a clinical setting.
A biomarker is a biological molecule found in blood or other body fluids or body tissues, that is a sign of a normal or abnormal process, condition, or disease. According to the study, miR- 370 gene level in blood was found to be a better biomarker than miR-375 for its potential and sensitivity to screen pediatric AML patients and more significant correlation with AML risk
The study was conducted in collaboration with some local prestigious local universities. It is noteworthy that the CCHE57357’sgenomics unit is the first of its kind in Egypt, prepared with a full pipeline of equipment to support research in various disciplines such as whole genome sequencing, whole exome sequencing, microbiome profiling, RNA sequencing, and other disciplines.